Biosearch Technologies Licenses New Flu Signatures from CDC | GenomeWeb

Biosearch Technologies said today that it has licensed from the US Centers for Disease Control and Prevention new H1N1 influenza probes and primers for more sensitive and specific H1N1 detection assays.

In April 2009, following the outbreak of novel 2009 H1N1 and concurrently circulating seasonal flu A and B viruses, the CDC designed and validated molecular diagnostic probes and primers, or signatures, used in real-time PCR detection assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.